Director/PDMR Shareholding

RNS Number : 0604R
Medica Group PLC
02 November 2021
 

Medica Group PLC

Director / PDMR Transaction and Shareholding

Medica Group PLC (LSE: MGP, "Medica" or the "Company"), has received notification from Dr Stuart Quin, Chief Executive Officer, that on 1 November 2021 he transferred a total of 26,546 ordinary shares of 0.2p in the Company ("Shares") to his spouse, Mallika Kaviratne, for nil consideration.

Following this transaction, there has been no change in the number of shares in which Stuart Quin has an interest.

The Notification of Dealing Forms can be found below.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and set out more details of the transactions.

 1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Stuart Quin

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Medica Group PLC

b)

 

LEI

 

213800B8XE5FUSZF5Z16

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.2p

 

GB00BYV24996

 

 

b)

 

Nature of the transaction

 

Transfer of Ordinary Shares to Mallika Kaviratne

c)

Price(s) and volume(s)

 

 

 

 

Price (s)

Volumes (s)

N/A

26,546

 

 

 

 

d)

 

Aggregated information

-  Aggrated volume

-  Price

 

 

26,546

N/A

 

e)

 

Date of the transaction

 

1 November 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

For further information, please contact:

 

Medica Group Plc:

Stuart Quin, Chief Executive Officer

Richard Jones, Chief Financial Officer

 

+44 (0)33 33 111 222

 

FTI Consulting

Victoria Foster Mitchell

Sam Purewal

+44 (0)20 3727 1000

 

Investec Bank plc (Joint Broker)

Sara Hale

Daniel Adams

Virginia Bull

 

+44 (0)20 7597 5970

Liberum (Joint Broker)

Bidhi Bhoma

Richard Lindley

Euan Brown

+44 (0)20 3100 2000

 

 

About Medica Group PLC

 

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

 

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

 

The Company currently offers two primary services to hospital radiology departments:

 

·   NightHawk - urgent reporting service

·   Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

 

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

 

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit: www.medicagroupplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKBBPCBDKFDK

Companies

Medica Group (MGP)
UK 100